The following is a summary of the VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• VolitionRx recorded revenue of $775,000 for the full year 2023, a significantly higher rate compared to the previous year.

• The Q4 revenue showed significantly higher results of $244,000, which is a 104% increase year-on-year.

• Net cash generated from operating activities reached approximately $6.4 million during Q4 and there was a net loss of $8.8 million for the same period.

• By end of the year, the company had $20.7 million in cash and cash equivalents.

• In the full year 2023, net cash used for operating activities was $18.1 million, and the net loss came to $35.7 million.

Business Progress:

• The company's Nu.Q Vet cancer test and Nu.Q discover pipeline observed a considerable increase in revenue, earning $475,000 and $300,000 respectively.

• VolitionRx has strategic partnerships to increase market presence, partnering with IDEXX, Heska Corporation and Fujifilm Vet Systems across multiple regions.

• VolitionRx has ambitious plans for 2024, projecting doubling of Nu.Q Discover revenue and expecting Nu.Q Vet's strong growth to continue with its global and regional partners.

• Looking forward, the company aims to achieve financial stability through non-dilutive funding, milestone payments, licensing deals, and product revenues.

• In their path for expansion, VolitionRx introduced a new method for detecting circulating tumor DNA (ctDNA), called Capture-PCR and is in discussions to license this technology.

More details: VolitionRX IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.